These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11897288)

  • 21. Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences.
    Stöllberger C; Finsterer J
    South Med J; 2004 Feb; 97(2):209. PubMed ID: 14982279
    [No Abstract]   [Full Text] [Related]  

  • 22. Balancing the risks and benefits of celecoxib.
    Caldwell B; Beasley R; Weatherall M; Metcalfe S
    Am J Med; 2007 Jun; 120(6):e17. PubMed ID: 17524734
    [No Abstract]   [Full Text] [Related]  

  • 23. Nephrotic syndrome and interstitial nephritis associated with celecoxib.
    Alper AB; Meleg-Smith S; Krane NK
    Am J Kidney Dis; 2002 Nov; 40(5):1086-90. PubMed ID: 12407655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
    Liccardi G; Salzillo A; Piccolo A; Senna G; Piscitelli E; D'Amato M; D'Amato G
    Eur Ann Allergy Clin Immunol; 2005 Feb; 37(2):50-3. PubMed ID: 15859361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute hepatocellular and cholestatic injury in a patient taking celecoxib.
    Nachimuthu S; Volfinzon L; Gopal L
    Postgrad Med J; 2001 Aug; 77(910):548-50. PubMed ID: 11470953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Celecoxib-induced upper gastrointestinal hemorrhage and ulceration.
    Crawford AS; White JG
    South Med J; 2002 Dec; 95(12):1444-6. PubMed ID: 12597315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Gastrointestinal damage induced by celecoxib and rofecoxib in rats].
    Laudanno OM; Cesolari JA; Esnarriaga J; Rista L; Piombo G; Maglione C; Aramberry LJ; Sambrano JS; Godoy A; Rocaspana A
    Acta Gastroenterol Latinoam; 2000; 30(1):27-33. PubMed ID: 10855352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
    Mamdani M; Juurlink DN; Lee DS; Rochon PA; Kopp A; Naglie G; Austin PC; Laupacis A; Stukel TA
    Lancet; 2004 May; 363(9423):1751-6. PubMed ID: 15172772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does celecoxib use increase the risk of cardiovascular events?
    Oviedo JA; Schroy PC
    Gastroenterology; 2005 Oct; 129(4):1348-50. PubMed ID: 16230088
    [No Abstract]   [Full Text] [Related]  

  • 30. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Severe cutaneous drug reactions to celecoxib (Celebrex)].
    Marquès S; Milpied B; Foulc P; Barbarot S; Cassagnau E; Stalder JF
    Ann Dermatol Venereol; 2003 Nov; 130(11):1051-5. PubMed ID: 14724542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Celecoxib (Celebrex): 1 year later.
    McMorran M; Morawiecka I
    CMAJ; 2000 Apr; 162(7):1044-6, 1048-50. PubMed ID: 10763409
    [No Abstract]   [Full Text] [Related]  

  • 33. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
    Hudson M; Richard H; Pilote L
    BMJ; 2005 Jun; 330(7504):1370. PubMed ID: 15947399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
    Bensen WG; Fiechtner JJ; McMillen JI; Zhao WW; Yu SS; Woods EM; Hubbard RC; Isakson PC; Verburg KM; Geis GS
    Mayo Clin Proc; 1999 Nov; 74(11):1095-105. PubMed ID: 10560596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclooxygenase (COX-2) selective inhibitors. Any better than NSAIDs?
    Nguyen A; Chaiton A
    Can Fam Physician; 2001 Jul; 47():1398-400. PubMed ID: 11494927
    [No Abstract]   [Full Text] [Related]  

  • 39. Celecoxib for rheumatoid arthritis.
    Megeff CE; Strayer SM
    J Fam Pract; 2000 Feb; 49(2):108-9. PubMed ID: 10718683
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy and safety of diclofenac-cholestyramine and celecoxib in osteoarthritis.
    Suárez-Otero R; Robles-San Román M; Jaimes-Hernández J; Oropeza-De La Madrid E; Medina-Peñaloza RM; Rosas-Ramos R; Castañeda-Hernández G
    Proc West Pharmacol Soc; 2002; 45():26-8. PubMed ID: 12434517
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.